Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase Program for Hyperuricemia in Pediatric Patients at Risk of Tumor Lysis Syndrome
2014-003989-24Phase 4
- Sponsor
- Sanofi
- Start
- Dec 2014
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rasburicase in hyperuricemia, tumor lysis syndrome (TLS) and hematopoietic malignancies, sponsored by Sanofi. Primary endpoints: Effectiveness in correcting hyperuricemia and Safety of rasburicase.
02
Drugs
rasburicase
03
Conditions
hyperuricemiatumor lysis syndrome (TLS)hematopoietic malignancies
Beyond the preview
Go deeper on 2014-003989-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003989-24.